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Background: The influence of parity and time interval between age at first pregnancy (AFP) and age at diagnosis
on breast cancer survival is not established in the same way as their influence on breast cancer risk. We aimed to
investigate the association of time interval or parity with prognosis in pre- and postmenopausal women in Korea.
Methods: We conducted a retrospective study of 29,167 women with breast cancer through the Korean Breast Cancer
Registry from 1993–2009. Information on reproductive factors, including breastfeeding, AFP, and parity were collected
from a routine questionnaire. Conditional logistic regression was used to estimate the associations between menopausal
status and overall mortality (OM) and breast-cancer-specific mortality (BCSM), adjusting for treatment and stage.
Results: High parity (≥5) increased the hazard ratios (HR) of BCSM (HR = 1.33, 95% confidence interval (CI): 0.83–2.11,
p < 0.001) and OM (HR = 1.20, 95% CI: 0.85–1.68.73, p < 0.001) in premenopausal and postmenopausal women (BCSM,
HR: 1.62, 95% CI: 0.93–2.82, p < 0.001; OM, HR = 1.58, 95% CI: 1.14–2.21, p <0.001). A longer time interval between age at
breast cancer diagnosis and AFP reduced the HRs of BCSM (HR = 0.97, 95% CI: 0.96–0.98, p = 0.001) and OM (HR = 0.98,
95% CI: 0.97–0.98, p < 0.001) in premenopausal women, but had an adverse effect on the HR of OM (HR = 1.03, 95% CI:
1.02–1.03, p < 0.001) in postmenopausal women.
Conclusions: High parity (≥5) was associated with poor breast cancer prognosis in both pre- and postmenopausal
women. The time intervals between reproductive events had different effects on breast cancer outcomes depending
on menopausal status.
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An early age at first pregnancy has been shown to be
protective in terms of lifetime risk of breast cancer. This
protective effect may be explained by the differentiation
of breast tissues induced by a full-term pregnancy,
resulting in lower susceptibility to carcinogenic influ-
ences [1]. However, events considered to be protective
in terms of breast cancer risk, such as early age at first
pregnancy and increased parity, may have an adverse* Correspondence: gsjslee@gmail.com
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unless otherwise stated.effect on breast cancer progression in women who are
diagnosed with the disease. It is possible that the timing
of reproductive events in relation to the initiation and
promotion of breast cancers may be critical in determin-
ing their effects in women who develop breast cancer
during their principal reproductive years [2].
Epidemiological studies have suggested that the en-
dogenous host environment, including reproductive his-
tory, body mass index, and BRCA germline mutation, may
correlate with breast cancer features and prognosis [3-11].
However, retrospective case–control studies of the rela-
tionship between breast cancer survival and host-related
reproductive factors have tended to report inconsistent re-
sults [12-14]. Reproductive factors may induce permanentLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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stromal tissue, and the most prominent effects may be re-
lated to the occurrence and timing of pregnancy [15,16].
It is possible that the tissue changes associated with
pregnancy may make the breast more or less susceptible
to carcinogenic factors [15], and the resulting effects
may also depend on the underlying genetic susceptibility
to breast cancer [17]. It is therefore possible that factors
related to age at menarche, the timing of pregnancies,
the prevalence of breastfeeding, and age at menopause
may either initiate or inhibit specific types of breast can-
cers with different degrees of aggressiveness.
Information from the Korean Breast Cancer Society
showed that reproductive factors, including early menar-
che, late menopause, late first birth and no breastfeeding
increased steadily in Korean women with breast cancer
from 1996 to 2004 [18]. Reproductive events associated
with tumor initiation or progression mostly occurred in
the premenopausal period. Furthermore, the proportion of
premenopausal breast cancer in Korea was higher than in
Western countries [12,18]. We previously reported the re-
lationship between reproductive breast risk factors and
breast cancer survival by breast cancer subtypes [19]. High
parity (≥4) and early age at first pregnancy (<20 years)
were correlated with worse outcomes in patients with lu-
minal breast cancer, but not with other subtyped breast
cancers. The time intervals between reproductive events,
such as age at menarche, AFP, and age at diagnosis, may
also differ according to menopausal status, which may also
affect the impact of these factors on clinical outcome. The
present study examined the impact of host-related repro-
ductive factors on breast cancer prognosis according to
pre- or postmenopausal status.
Methods
Study population
Patients diagnosed with breast cancer who were regis-
tered in the Korean Breast Cancer Society Registry be-
tween January 1993 and December 2009 were studied
retrospectively. 71.7% of Korean breast cancer patients
were registered in the Korean Breast Cancer Society
Registry. A total of 29,167 patients were registered by
102 general hospitals, including 41 university hospitals
and 61 surgical training hospitals. The database provided
information about sex, age, type of operation, stage ac-
cording to the 6th American Joint Committee on Cancer
(AJCC) classification, histological findings, and presence
of biological markers, adjuvant therapy, survival, and the
cause of death, which was obtained from the Ministry
of Health and Welfare, Republic of Korea. The Korean
Breast Cancer Society Registry has been described in de-
tail elsewhere [12]. The following exclusion criteria were
used: (a) male, (b) women who gave birth after breast
cancer diagnosis, and (c) no available reproductive data.Information on patient age, demographics, reproductive
variables (age at menarche, pregnancy and childbirth his-
tory, breastfeeding, AFP, use of oral contraceptives, and
use of hormone-replacement therapy) were collected from
personal interviews conducted with each patient at the
time of diagnosis. Participants were considered to be post-
menopausal if they reported that their menstrual cycles
had stopped for at least 12 months prior to their breast
cancer diagnosis. Body mass index was calculated based
on body weight at diagnosis and the reported maximum
body height. Use of hormone replacement therapies was
defined as never, former use, or current use. The tumor
characteristics at the time of diagnosis (tumor size, hist-
ology, stage, and estrogen receptor (ER), progesterone re-
ceptor (PR), and HER2 expression) were determined on
the basis of pathology reports in 28,989 of the patients
who were registered in the cancer registry database. The
tumors were staged using the TNM staging system, which
follows the AJCC criteria and involves the assignment of
appropriate letters or numbers to the following three
fields: T (primary tumor), N (nodal involvement), and M
(distant metastasis) [20]. This classification was recorded
for both clinical and pathological staging. ER and PR ex-
pression were recorded as either negative or positive,
while a HER2 status of 0, 1+ or 2+ was considered nega-
tive and 3+ was considered positive. This study was ap-
proved by the ethics committee at University of Inje.
Statistical analyses
Patient groups were compared using χ2 tests for discrete
data. The results of all tests were considered significant at
p values of <0.05. Multivariate Cox proportional hazard
models were used to determine the effects of reproductive
factors on breast-cancer-specific mortality, (BCSM; death
due to breast cancer) and overall mortality (OM;death
from any cause). All analyses were adjusted for potential
prognostic factors and stratified for menopausal status.
Hazard ratios (HR) and 95% confidence intervals (CI)
were calculated for the following study factors: AFP
(<20 years, 20–24, 25–29 years, ≥30 years); number of
children before diagnosis (0, 1, 2, 3, 4, ≥5); and breastfeed-
ing history in parous women (never, ever). Trends in time
intervals between age at diagnosis and AFP, or between
AFP and menarche were determined by linear regression
for continuous data. All analyses were performed using
SAS version 8.2 (SAS institute Inc., Cary, NC, USA). In
this manuscript we confirm that our research have ad-
hered to the STROBE guidelines (Additional file 1).
Results
Reproductive factors and tumor characteristics
Mean age of total patients was 48.3 (±10.5) years old, that
of premenopausal patients was 44.8 (±9.1) years old, and
that of postmenopausal patients was 57.7 (±8.0) years old.
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postmenopausal than in premenopausal breast cancer
patients (84.9% versus 82.3%, p < 0.001). Lymph node
metastasis (39.8% versus 38.0%, p < 0.001) and ER posi-
tivity (60.7% versus 57.1%, p < 0.001) were more frequent
in premenopausal breast cancer patients, while Her-2/
neu positivity was more common in postmenopausal
than in premenopausal breast cancer patients (24.5%
versus 23.2%, p = 0.026). Early AFP (≤24 years) (17.1%
versus 44.4%, p < 0.001), and high parity (≥5) (1.3% ver-
sus 9.7%, p < 0.001) were more frequent in postmeno-
pausal breast cancer patients (Table 1).
Association between reproductive factors and breast
cancer survival stratified by menopausal status.
AFP
Compared with nulliparity, any AFP decreased the HRs
of BCSM and OM in premenopausal breast cancer pa-
tients. However, early AFP (≤20 years) and late AFP




T1,2 24051 82.9 17378
T3,4 2235 17.1 1682
LN involvement
(−) 17591 60.7 12714
(+) 11398 39.3 8412
ER
(−) 10701 40.3 7527
(+) 15829 59.7 11608
HER2
(−) 18217 76.5 13263
(+) 5605 23.5 3996
Age at first pregnancy (years)
Nulliparous 4943 19.08 4441
<20 520 2.01 202
20-24 6653 25.68 3756
25-29 10923 42.16 8114
≥30 2871 11.08 2178
Parity
Nulliparous 4943 17.05 4441
1 3874 13.36 3095
2 13269 45.77 10458
3 4345 14.99 2363
4 1523 5.25 496
≥5 1035 3.57 273CI: 0.76–2.89 and HR = 1.50, 95% CI: 0.85–2.67, respect-
ively) and OM (HR = 1.40, 95% CI: 0.94–2.09 and HR =
1.18, 95% CI: 0.83–1.68, respectively) (p <0.001) in post-
menopausal breast cancer patients (Table 2). The me-
dian (±standard deviation) follow-up duration was 13.4
(±1.9) years in premenopausal women, and 11.7 (±4.2)
years in postmenopausal women.
Parity
Compared with nulliparity, high parity (≥5) significantly in-
creased the HRs of BCSM (HR = 1.32, 95% CI: 0. 83–2.11)
and OM (HR = 1.20, 95% CI: 0.85–1.68) in premenopausal
women, and also in postmenopausal women (p <0.0001)
(Table 3). The median follow up duration was 13.4 (±1.9)
years in premenopausal women and 11.7 (±4.2) years in
postmenopausal women.
Breastfeeding
Breastfeeding had no significant effect on the HR of ei-




























Table 2 Risks of breast-cancer-specific and overall survival according to age at first pregnancy stratified by
menopausal status
Premenopausal Postmenopausal
Case Events HR (95% CI) Case Events HR (95% CI)
AFP Breast cancer specific survival
Nulliparous 4441 269 Ref 502 17 Ref
<20 202 5 0.436 (0.180-1.057) 318 18 1.492 (0.769-2.896)
20-24 3756 100 0.429 (0.341-0.540) 2897 116 1.090 (0.655-1.813)
25-29 8114 193 0.376 (0.312-0.452) 2809 88 0.834 (0.496-1.403)
≥30 2178 51 0.372 (0.275-0.501) 693 38 1.508 (0.851-2.673)
p-value <.0001 0.0172
AFP Overall survival
Nulliparous 4441 561 Ref 502 47 Ref
<20 202 16 0.672 (0.409-1.105) 318 49 1.404 (0.941-2.095)
20-24 3756 274 0.551 (0.477-0.637) 2897 332 1.076 (0.793-1.460)
25-29 8114 513 0.468 (0.415-0.528) 2809 231 0.748 (0.546-1.023)
≥30 2178 159 0.547 (0.459-0.653) 693 87 1.183 (0.830-1.687)
p-value <.0001 <.0001
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pausal or postmenopausal breast cancer patients (BCSM,
HR = 0.80, 95% CI: 0.58–1.10, p = 0.17; OM, HR = 0.98,
95% CI: 0.80–1.20, p = 0.86) (Table 4).
Time interval between reproductive events
A longer time interval between AFP and menarche sig-
nificantly decreased the HR of BCSM (HR = 0.96, 95%Table 3 Risks of breast-cancer-specific and overall survival ac
Premenopausal
Case Events HR (95% C
Parity Brea
Nulliparous 4441 269 Ref
1 3095 87 0.463 (0.363-0
2 10458 257 0.386 (0.326-0
3 2363 84 0.574 (0.449-0
4 496 27 0.905 (0.609-1
≥5 273 19 1.329 (0.835-2
p-value <.0001
Parity
Nulliparous 4441 561 Ref
1 3095 252 0.641 (0.552-0
2 10458 699 0.497 (0.444-0
3 2363 178 0.570 (0.482-0
4 496 57 0.880 (0.670-1
≥5 273 36 1.204 (0.859-1
p-value <.0001CI: 0.93–0.99, p < 0.009) but had no effect on the HR of
OM (HR = 0. 99, 95% CI: 0.97–1.00, p = 024) in premen-
opausal breast cancer patients (Table 5). A longer time
interval between AFP and age at diagnosis reduced the
HRs of BCSM (HR = 0.97, 95% CI: 0.96–0.98, p < 0.001)
and OM (HR = 0.98, 95% CI: 0.97–0.98, p < 0.001) in
premenopausal breast cancer patients, but had no sig-
nificant effect on BCSM, but a longer time intervalcording to parity stratified by menopausal status
Postmenopausal
I) Case Events HR (95% CI)
st cancer specific survival
502 17 Ref
.590) 779 36 1.338 (0.752-2.383)
.458) 2811 100 0.986 (0.590-1.650)
.733) 1982 57 0.750 (0.436-1.289)
.345) 1027 42 1.079 (0.614-1.896)




.743) 779 81 1.056 (0.737-1.513)
.555) 2811 231 0.806 (0.589-1.103)
.675) 1982 174 0.789 (0.572-1.090)
.155) 1027 123 1.065 (0.761-1.491)
.687) 762 139 1.587 (1.140-2.210)
<.0001
Table 4 Risks of breast-cancer-specific and overall survival according to breastfeeding history stratified by menopausal
status
Premenopausal Postmenopausal
Case Events HR (95% CI) Case Events HR (95% CI)
Breast feeding Breast cancer specific survival
Yes 10794 297 1.083 (0.890-1.319) 6176 218 0.803 (0.586-1.101)
No 5820 149 Ref 1122 47 Ref
p-value 0.4267 0.1726
Breast feeding Overall survival
Yes 10794 751 0.916 (0.814-1.030) 6176 619 0.982 (0.800-1.206)
No 5820 445 Ref 1122 107 Ref
p-value 0.1412 0.8612
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OM in postmenopausal breast cancer patients (HR =
1.03, 95% CI: 1.02–1.03, p < 0.001) (Table 6).
Discussion
A relatively young AFP is primarily associated with a re-
duced risk of lower grade, ER-positive breast cancer [3,20],
which is generally associated with better survival than high-
grade, ER-negative tumors [21]. This suggests that women
with a young AFP who develop breast cancer may be more
likely to have ER-negative, high-grade tumors, which could
explain the association between early first pregnancy and
poor prognosis reported in some studies. Early age at diag-
nosis has also been associated with a poor prognosis in
some studies [22-24]. However, the biologic processes
underlying these findings are not well understood, and
probably involve a combination of inheritance [25], tumor
gene expression in young women [21], and the hormonal
milieu in premenopausal compared with postmenopausal
women. In contrast, a late age at first pregnancy has been
associated with higher risk of more aggressive ER-positive
breast tumors in some studies [26,27]. Therefore, both early
and late AFP may be associated with poor survival, though
the underlying biological mechanisms may differ.
The results of this study suggest that parity, irrespective
of AFP, was associated with a more favorable prognosis inTable 5 Risks of breast-cancer-specific and overall survival ac
Premenopausal
Case Events HR (9
AFB-age of menarche
14057 339 0.965 (0.9
p-value 0.0
AFB-age of menarche
14057 938 0.990 (0.9
p-value 0.2terms of BCSM and OM compared with nulliparity in
premenopausal women, though both early (<22 years)
and late AFP may be associated with poor survival in
postmenopausal women. Some studies reported no as-
sociations [27,28], while others found that poorer sur-
vival was associated with an early AFP [23,29]. Alsaker
et al. [30] reported that late AFP may be associated with
a poorer prognosis among women with postmenopausal
breast cancer.
Pregnancy-related factors may result in long-term
changes in the hormonal milieu [31]. However, although
high parity clearly protects against breast cancer [32], its
protective effect may be limited to ER-positive tumors [3],
and it has been suggested that high parity may conversely
increase the risk of triple-negative breast cancer [30],
which is known to have a poor prognosis [9] and to be
more common in younger women [33]. A similar but
smaller study also found that high parity may have a pro-
tective effect against small and low-grade tumors [25,26],
with the consequence that women with high parity may
tend to have relatively advanced and aggressive disease. In
this study, high parity (≥5) increased the HRs of BCSM
and OM in premenopausal breast cancer patients, and this
effect was attenuated beyond menopause. Compared with
nulliparity, both single parity and high parity (≥5) were
positively associated with high mortality from breast cancercording to time interval from AFB to menarche
Postmenopausal
5% CI) Case Events HR (95% CI)
Breast cancer specific survival
39-0.991) 6579 251 0.983 (0.955-1.013)
095 0.2621
Overall survival
75-1.007) 6579 678 0.961 (0.943-0.979)
455 <.0001
Table 6 Risks of breast-cancer-specific and overall survival according to time interval from AFB to age at diagnosis
Premenopausal Postmenopausal
Case Events HR (95% CI) Case Events HR (95% CI)
Age at diagnosis-AFB Breast cancer specific survival
14387 352 0.975 (0.962-0.989) 6761 261 1.005 (0.992-1.018)
p-value 0.0003 0.4578
Age at diagnosis-AFB Overall survival
14387 969 0.981 (0.973-0.989) 6761 701 1.031 (1.023-1.038)
p-value <.0001 <.0001
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pausal hormonal milieu may alter the protective effect of
childbirth. In contrast to this, some studies demonstrated
that nulliparous women had better survival than parous
women, whereas the association was reversed in postmen-
opausal women [23,34].
It is therefore unclear if the association between high par-
ity and overall survival in the current study reflects a gen-
eral decrease in female survival associated with high parity,
as a result of deaths due to parity-related diseases such as
cardiovascular disease, and postpartum related diseases,
without specifically affecting the course of breast cancer.
High parity might then be expected to have a greater effect
on overall survival in postmenopausal women, in terms of
mechanisms such as socioeconomic effects, and general
health care [28,29].
Several recent studies have shown that the first preg-
nancy induces a specific genomic signature in the breast
epithelium [14,35]; inflammation-associated genes were
up-regulated in premenopausal parous human breast tis-
sue, and Her-2/neu expression was changed relative to
nulliparous human breast tissue from the same gener-
ation [35]. The genomic profile of breast cancer cases,
irrespective of parity history, differed from those of par-
ous or nulliparous cancer-free cases, according to hier-
archical clustering [14]. These findings suggest that the
breast cancer cells were already generated before preg-
nancy, and that pregnancy contributed to the prevention
of mammary carcinogenesis. Parous subjects had signifi-
cantly reduced expression of ERα (ERE, ESR1), PR, and
ErbB2 (Her-2/neu), and 2-fold higher expression of ERβ
(ESR2) compared with nulliparous subjects. These differ-
ences in the expression profiles of the hormone signaling
genes ESR1, ESR2, PR, and ERBB2 indicate parity-
mediated protective effects.
Lactation is believed to be associated with decreased
circulating levels of estrogen and progesterone, and was
hypothesized to be associated with earlier-stage tumors
with less aggressive profiles. Lactation among parous
women was not found to be associated with tumor stage,
though parous women who had breastfed a child were
more likely to have ER-positive and PR-positive tumorsthan were parous women who had never breastfed [3].
This effect would explain a small benefit associated with
breastfeeding, given that the prevalence of ER-negative
tumors may be lower among parous women who have
breastfed compared with those who have never breast-
fed. Lactation was therefore associated with tumor
markers indicative of better prognosis [36]. We were un-
able to assess these effects in relation to breastfeeding,
but our results were in line with those of other studies
that showed no consistent association between breast
cancer and breastfeeding [37].
The time interval from childbirth until diagnosis has
been related to the prognosis of breast cancer in other
large registry-based studies [23,29,38]. Women diag-
nosed with breast cancer close to a pregnancy tend to be
younger and have a more advanced stage of disease [39],
higher histological grade [25], and are more likely to
have ER-negative tumors [40]. Several studies have
shown that breast cancer patients who gave birth shortly
before diagnosis had poorer survival outcomes than nul-
liparous patients or those with a less recent childbirth
[17,41]. Even after adjusting for these well-known prog-
nostic factors, including AJCC stage, hormone receptor
and Her-2/neu statuses, and histological tumor grade,
women who delivered within 2 years of breast cancer
diagnosis had a 2-fold increased risk of death compared
with nulliparous women [11].
During pregnancy and subsequent lactation, the breast
tissue evolves from an immature to a fully-developed
state, associated with rapid cell turnover during and after
pregnancy. High parity might thus eventually enhance
the initiation or progression of malignant tumor cells.
Daling et al. [40] reported that women diagnosed with
breast cancer less than 2 years after childbirth had a
relatively high proportion of p53-positive, PR-negative,
lymph node-positive and grade III tumors, which could
result from the progression of highly malignant cells
during and after pregnancy.
Several hypotheses have been proposed to explain the
poor prognosis of young breast cancer patients who have
recently given birth. The gestational hormones estrogen,
progesterone, and insulin-like growth factor increase tumor
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ment of pregnancy may influence the biology of more ag-
gressive tumor types. Asztalos et al. [35] investigated if
pregnancy and involution were associated with gene ex-
pression changes in the normal breast, and whether such
changes were transient or persistent. They found that 22%
of the selected gene set related to immune/inflammation,
extracellular matrix remodeling, angiogenesis, and hor-
mone signaling was differentially regulated in nulliparous
versus parous breast tissues.
Pregnancy is associated with persistent changes in gene
expression in normal breast tissue, which may contribute
to the protective and stimulatory effects of pregnancy on
breast cancer risk. Pregnancy appears to have a lasting ef-
fect on gene expression, which is detectable for up to
10 years and possibly even longer. Recent evidence suggests
that ERα and ErbB2 collaborate in mediating estrogen-
induced mitogenesis, and down regulation of ErbB2 in par-
ous women may also be linked to a protective effect [43].
Russo and coworkers [44] used cDNA microarray analysis
of ethanol-fixed tissue from postmenopausal women and
showed that many genes were differentially expressed be-
tween parous and nulliparous women, including a number
of immune-related genes that were up-regulated in the
parous group.
Although the number of patients in the current study
was moderate, follow-up was almost complete, and the
lower number of breast cancer deaths ensured a rela-
tively high statistical power for detecting important dif-
ferences. However, the strength of the detected
associations was typically weak, and we cannot rule out
the possibility that some of the findings of the study may
be explained by chance. Another weakness of this study
may be the lack of detailed clinical information, both at
diagnosis and during follow-up.
This study analyzed the HRs after adjusting for repro-
ductive factors and tumor characteristics, including hor-
mone receptor and Her-2/neu status and T stage, but we
cannot exclude the possibility of residual confounding.
Nevertheless, any remaining confounder that could in-
fluence the results would need to be strongly associated
with breast cancer survival, as well as the reproductive
factors under study, and be simultaneously unrelated to
the confounders included in the analyses.
Conclusions
We found that early AFP (<20 years) and late AFP
(≥30 years) were associated with poorer breast cancer
survival in postmenopausal breast cancer patients, but
any AFP showed better clinical outcomes than nullipar-
ity in premenopausal breast cancer patients. High parity
(≥5) was associated with poorer clinical outcomes in
pre- and postmenopausal women with breast cancer. How-
ever, we found no clear relation between breastfeeding andbreast cancer survival in pre- or postmenopausal breast
cancer patients.
Socioeconomic changes and pressures on young women
in Korea mean that most younger women tend to have
jobs and to delay getting married and having children, and
therefore have a later AFP, and only breastfeed for a short
period [19]. Further follow-up of existing prospective co-
hort studies is needed to confirm and clarify these rela-
tionships, especially for different tumor subtypes. In
addition, more studies are needed to characterize the rela-
tionships between parity and various outcomes in breast
cancer patients.
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